Please login to the form below

Not currently logged in
Email:
Password:

Caprelsa

This page shows the latest Caprelsa news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China

Meanwhile, other orally-active drugs that target VEGF – including Bayer’s Nexavar (sorafenib), Novartis’ Votrient (pazopanib), and Sanofi’s Caprelsa (vandetanib) – have been developed for a range of other solid tumours

Latest news

  • AZ sells rare cancer drug to Sanofi AZ sells rare cancer drug to Sanofi

    Sanofi's rare diseases unit Genzyme will pay AstraZeneca up to $300 million for the global rights to the firm's rare disease drug Caprelsa (vandetanib). ... Caprelsa is not however a blockbuster drug and saw sales of just $48m last year.

  • Eisai’s thyroid cancer drug Lenvima nears EU approval Eisai’s thyroid cancer drug Lenvima nears EU approval

    AstraZeneca also has a thyroid cancer drug in the form of Caprelsa(vandetanib), although this has a different licence, namely for the treatment of aggressive and symptomatic medullary thyroid cancer in

  • Eisai given early approval for new oncology drug Eisai given early approval for new oncology drug

    In 2012 the EMA gave the green light to AstraZeneca's Caprelsa (vandetanib), although this is for a different form of the disease, specifically for the treatment of aggressive and symptomatic

  • CHMP recommends AZ's thyroid cancer drug Caprelsa for approval

    European regulatory advisors have given the green light to AstraZeneca's thyroid cancer treatment Caprelsa (vandetanib). ... The CHMP issued a positive opinion on Caprelsa's use against aggressive and symptomatic medullary thyroid cancer (MTC) in

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics